Itacitinib
- Generic Name
- Itacitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23F4N9O
- CAS Number
- 1334298-90-6
- Unique Ingredient Identifier
- 19J3781LPM
- Background
Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Michael Savona
- Target Recruit Count
- 105
- Registration Number
- NCT04061421
- Locations
- πΊπΈ
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
- Conditions
- Recurrent T-Cell Prolymphocytic LeukemiaT-Cell Prolymphocytic Leukemia
- Interventions
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03989466
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 23
- Registration Number
- NCT03978637
- Locations
- πΊπΈ
Brigham and Women'S Faulkner Hospitals Inc, Boston, Massachusetts, United States
πΊπΈTemple University Department of Thoracic Medicine and Surgery, Philadelphia, Pennsylvania, United States
π§πͺUniversitaire Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium
Itacitinib for Low Risk GVHD
- Conditions
- Low Risk Acute Graft-versus-host DiseaseGraft-versus-host-diseaseGVHD
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- John Levine
- Target Recruit Count
- 70
- Registration Number
- NCT03846479
- Locations
- πΊπΈ
The Mount Sinai Hospital, New York, New York, United States
πΊπΈOhio State University, Columbus, Ohio, United States
πΊπΈChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
- Conditions
- Myelodysplastic SyndromesAcute Myelogenous LeukemiaAcute Lymphocytic LeukemiaHodgkin DiseaseNon-Hodgkin Lymphoma
- Interventions
- Procedure: Stem cell transplantationOther: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)Other: Human Activity Profile
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT03755414
- Locations
- πΊπΈ
Washington University School of Medicine, Saint Louis, Missouri, United States
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
- Conditions
- Acute Graft-versus-host Disease
- Interventions
- Drug: Corticosteroids
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT03721965
- Locations
- πΊπΈ
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
πΊπΈDuke University Medical Center, Durham, North Carolina, United States
πΊπΈUniversity Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
Itacitinib + Everolimus in Hodgkin Lymphoma
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 23
- Registration Number
- NCT03697408
- Locations
- πΊπΈ
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
- Conditions
- Metastatic LeiomyosarcomaMetastatic Undifferentiated Pleomorphic SarcomaRefractory Undifferentiated Pleomorphic SarcomaAdvanced Synovial SarcomaAdvanced Undifferentiated Pleomorphic SarcomaAdvanced LeiomyosarcomaMetastatic Synovial SarcomaRefractory LeiomyosarcomaRefractory Round Cell LiposarcomaRefractory Soft Tissue Sarcoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT03670069
- Locations
- πΊπΈ
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
- Conditions
- Moderate to Severe Ulcerative Colitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03627052
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- Conditions
- Chronic Graft-versus-host Disease
- Interventions
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 155
- Registration Number
- NCT03584516
- Locations
- πΊπΈ
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
πΊπΈLoyola University Medical Center, Maywood, Illinois, United States
πΊπΈJefferson University Hospitals, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.